Kashiwagi, S., Asano, Y., Goto, W., Takada, K., Takahashi, K., Hatano, T., Tanaka, S., Takashima, T., Tomita, S., Motomura, H., Ohsawa, M., Hirakawa, K. and Ohira, M. (2018) Mesenchymal-Epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer. Anticancer Res, 38, 401-410.

has been cited by the following article:

• TITLE: The Expression of E-Cadherin and Vimentin in Non-Small-Cell Lung Cancer and Their Correlation with Epithelial-Mesenchymal Transition (EMT)

  AUTHORS: Mingyuan Tian, Yu Li

  KEYWORDS: Lung Cancer, E-Cadherin, Vimentin, EMT

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.6 No.5, May 21, 2018

  ABSTRACT: To investigate the expression of E-cadherin and Vimentin protein in non-small-cell lung cancer (NSCLC) and to analyze the relationship between their expression and epithelial-mesenchymal transition (EMT). Immuno-chemical staining with SP method was conducted to detect the protein expression of E-cadherin and Vimentin in 44 lung cancer tissues. E-cadherin was highly expressed in all normal lung tissues, and Vimentin was lowly expressed in all normal lung tissues. The expression rate of E-cadherin and Vimentin was 40.9% and 25.0% in NSCLC cases. The expressions of E-cadherin and Vimentin were not associated with gender, age, histopathological grading, lymphatic metastasis or smoking status (P > 0.05). But they were associated with clinical stage (P